General Information of Drug Combination (ID: DCM5A9G)

Drug Combination Name
MK-4827 RTB101
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs MK-4827   DMLYGH4 RTB101   DM62QTW
Small molecular drug Small molecular drug
High-throughput Screening Result Testing Cell Line: T-47D
Zero Interaction Potency (ZIP) Score: 23.26
Bliss Independence Score: 23.21
Loewe Additivity Score: 23.77
LHighest Single Agent (HSA) Score: 25.9

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-4827
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 3 [2]
Breast cancer 2C60-2C65 Phase 2 [3]
Ewing sarcoma 2B52 Phase 1 [3]
MK-4827 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Poly [ADP-ribose] polymerase (PARP) TTEBCY8 NOUNIPROTAC Modulator [6]
------------------------------------------------------------------------------------
MK-4827 Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [7]
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Metabolism [8]
Beta-glucuronidase (GUSB) DEP54UE BGLR_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
MK-4827 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [9]
------------------------------------------------------------------------------------
Indication(s) of RTB101
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Phase 3 [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]
RTB101 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
CREB-regulated transcription coactivator 1 (TORC1) TT4GO0F CRTC1_HUMAN Inhibitor [10]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCD723T ES2 Investigative [11]
Breast and ovarian cancer syndrome DCU6HS1 UWB1289 Investigative [1]
Breast and ovarian cancer syndrome DC84CA9 UWB1289+BRCA1 Investigative [1]
Breast carcinoma DCN7SGM ZR751 Investigative [1]
Breast carcinoma DC87O78 KPL1 Investigative [1]
Breast carcinoma DCKIE1M OCUBM Investigative [1]
Carcinoma DCEELWL OV90 Investigative [1]
Carcinoma DCZIJID EFM192B Investigative [1]
Carcinoma DC2MZW9 MDAMB436 Investigative [1]
Colon adenocarcinoma DCK01CR LOVO Investigative [1]
Colon carcinoma DCP62QP RKO Investigative [1]
Rectal adenocarcinoma DC0MC7G SW837 Investigative [1]
Adenocarcinoma DC73NTU CAOV3 Investigative [12]
Adenocarcinoma DCRA69Y OVCAR3 Investigative [12]
Adenocarcinoma DC41PDY A427 Investigative [12]
Adenocarcinoma DCDD7TA NCIH1650 Investigative [12]
Adenocarcinoma DCXJT2O NCIH2122 Investigative [12]
Adenocarcinoma DCVSPSC NCIH23 Investigative [12]
Adenocarcinoma DCFMSGR NCIH520 Investigative [12]
Adenocarcinoma DCLO61D COLO320DM Investigative [12]
Adenocarcinoma DCP3DTI DLD1 Investigative [12]
Adenocarcinoma DCGIHIB HCT116 Investigative [12]
Adenocarcinoma DC2I1PQ HT29 Investigative [12]
Adenocarcinoma DC0SQ46 SW-620 Investigative [12]
Amelanotic melanoma DCMIY7Q A2058 Investigative [12]
Germ cell tumour DCE28IL PA1 Investigative [12]
Large cell lung carcinoma DCC4HKB NCI-H460 Investigative [12]
Malignant melanoma DC1SLZC HT144 Investigative [12]
Malignant melanoma DC5ENSD RPMI7951 Investigative [12]
Malignant melanoma DCVFPMO SKMEL30 Investigative [12]
Malignant melanoma DCBT7KV UACC62 Investigative [12]
Malignant melanoma DCDIM50 A375 Investigative [12]
Mesothelioma DCGNDWF MSTO Investigative [12]
Non small cell carcinoma DCTEKI5 SKMES1 Investigative [12]
Ovarian endometrioid adenocarcinoma DCICY6D A2780 Investigative [12]
Ovarian serous cystadenocarcinoma DCBA8UJ SK-OV-3 Investigative [12]
Prostate carcinoma DCMZVH6 LNCAP Investigative [12]
Prostate carcinoma DCCKFAM VCAP Investigative [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 38 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 ClinicalTrials.gov (NCT03602859) A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.
8 Summary of FDA-approved anticancer cytotoxic drugs at May 2019.
9 Autophagy up-regulated by MEK/ERK promotes the repair of DNA damage caused by aflatoxin B1. Toxicol Mech Methods. 2022 Feb;32(2):87-96. doi: 10.1080/15376516.2021.1968985. Epub 2021 Aug 26.
10 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
11 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
12 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.